Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides

被引:10
作者
Ghei, M
Stroncek, DF
Provenzano, M [1 ]
机构
[1] NIH, Mol Immunol Sect, Dept Transfus Med, Bethesda, MD 20892 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Univ Basel, Inst Chirurg Forsch & Spitalmanagement, Basel, Switzerland
关键词
D O I
10.1186/1479-5876-3-23
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The continuous efforts aimed at the identification of new immune epitopes across the MHC system has led to the discovery that more than one peptide may be restricted to the same HLA antigen and function as an immune determinant for that association. The aim of this study was to compare the ability of two overlapping peptides, the nonamer (9-mer) cytomegalovirus (CMV) pp65(341-349) (QYDPVAALF) and the decamer (10-mer) CMV pp65(341-350) (QYDPVAALFF), and the esadecamer (16-mer) peptide containing both the 9-mer and 10-mer sequences, CMV pp65(340-355) (RQYDPVAALFFFDIDL), to stimulate and maintain over time a T cell immune reactivation by HLA-A*2402, A*0101, and Cw*0402 cells from CMV-seropositive subjects. The 9-mer, 10-mer, and 16-mer peptides effectively stimulated CTLs from HLA-A*2402, HLA-A*0101, and HLA-Cw*0402 CMV seropositive donors. This data confirms that both the 9-mer and the 10-mer peptides are promiscuous and are not restricted to a single HLA antigen. CMV pp65(341-349) and CMV pp65(341-350) have the ability to produce CMV-specific CTLs in subjects with several different HLA types, presenting a practical advantage over other peptides that are restricted only to a single HLA antigen, and thus being optimal for CMV adoptive immune therapy. Moreover, since the 16-mer peptide encompasses both the 9-mer and 10-mer peptides, it may be better than either of these peptides for CMV adoptive immune therapy.
引用
收藏
页数:8
相关论文
共 15 条
[1]  
BRONKE C, 2005, DYNAMICS CYTOMEGALOV, V191, P873
[2]   Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy [J].
Einsele, H ;
Roosnek, E ;
Rufer, N ;
Sinzger, C ;
Riegler, S ;
Löffler, J ;
Grigoleit, U ;
Moris, A ;
Rammensee, HG ;
Kanz, L ;
Kleihauer, A ;
Frank, F ;
Jahn, G ;
Hebart, H .
BLOOD, 2002, 99 (11) :3916-3922
[3]  
HAKENBERG J, 2003, APPL BIOINFORMATICS, V3, P155
[4]   A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates [J].
Holzhütter, HG ;
Kloetzel, PM .
BIOPHYSICAL JOURNAL, 2000, 79 (03) :1196-1205
[5]   Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles [J].
Kondo, E ;
Akatsuka, Y ;
Kuzushima, K ;
Tsujimura, K ;
Asakura, S ;
Tajima, K ;
Kagami, Y ;
Kodera, Y ;
Tanimoto, M ;
Morishima, Y ;
Takahashi, T .
BLOOD, 2004, 103 (02) :630-638
[6]   Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay [J].
Kuzushima, K ;
Hayashi, N ;
Kimura, H ;
Tsurumi, T .
BLOOD, 2001, 98 (06) :1872-1881
[7]  
Lim JB, 2004, YONSEI MED J, V45, P18
[8]   The matrix protein pp65341-350:: a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele [J].
Provenzano, M ;
Lim, JB ;
Mocellin, S ;
Monsurro, V ;
Bettinotti, M ;
Marincola, FM ;
Stroncek, DF .
TRANSFUSION, 2003, 43 (11) :1567-1574
[9]   Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-γ production by peptide-stimulated peripheral blood mononuclear cells [J].
Provenzano, M ;
Mocellin, S ;
Bettinotti, M ;
Preuss, J ;
Monsurrò, V ;
Marincola, FM ;
Stroncek, D .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (04) :342-351
[10]   Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants [J].
Rauser, G ;
Einsele, H ;
Sinzger, C ;
Wernet, D ;
Kuntz, G ;
Assenmacher, M ;
Campbell, JDM ;
Topp, MS .
BLOOD, 2004, 103 (09) :3565-3572